Avleen Kaur
Montefiore Medical Center
Katherine Ni
Montefiore Medical Center
Won Kim
Seoul National University
Alyson Kaplan
New York-Presbyterian Hospital-Columbia
Osman Berk Usta
Massachusetts General Hospital
Treatment Option for Unresectable Hepatocellular Carcinoma
Supported by: AstraZeneca
This promotional program covers the HIMALAYA trial of the IMFINZI + IMJUDO immunotherapy regimen in patients with unresectable HCC. The presentation has been updated with results from the HIMALAYA 4-year exploratory analysis sho
An Exelixis Product for the Clinical Management of HCC
Supported by: An Exelixis Product for the Clinical Management of HCC
Presenter:
Julio A. Gutierrez, MD, MS
Terlipressin and Albumin Use in Hepatorenal Syndrome
Supported by: Mallinckrodt Pharmaceuticals
Presenter:
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
NIS4 and NIS2+: Promising Blood-based Biomarkers for NASH Clinical Trials and Patient Care
Supported by: Labcorp
NIS4® is a blood-based test designed to effectively identify patients with at-risk metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The more recently developed NIS2+™ is an optimized version of NIS4® that was